CJ
DGX icon

Caitlin John’s Quest Diagnostics DGX Stock Holding History

Caitlin John’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3
Closed -$640 – 1020
2026
Q1 		$640 Hold
3
– – ﹤0.01% 836
2025
Q4 		$564 Hold
3
– – ﹤0.01% 846
2025
Q3 		$617 Buy
+3
New +$532 ﹤0.01% 811
2025
Q1 		– Sell
-3
Closed -$481 – 284
2024
Q4 		$481 Hold
3
– – ﹤0.01% 788
2024
Q3 		$512 Hold
3
– – ﹤0.01% 780
2024
Q2 		$432 Sell
3
-2
-40% -$274 ﹤0.01% 780
2024
Q1 		$687 Sell
5
-2
-29% -$259 ﹤0.01% 783
2023
Q4 		$984 Buy
+7
New +$920 ﹤0.01% 758

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Caitlin John's DGX Position: Q2 2026 in Review

Caitlin John sold out of Quest Diagnostics (DGX) in Q2 2026, closing a stake of 3 shares — an estimated $640 sold.

Caitlin John first reported a position in DGX in Q4 2023 and held it in 8 quarters. The position peaked at $984 in Q4 2023. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Caitlin John reported no remaining Quest Diagnostics position as of Q2 2026 after selling out during the quarter.
  • Caitlin John sold 3 Quest Diagnostics shares in Q2 2026, an estimated $640.
  • Caitlin John first reported a position in Quest Diagnostics in Q4 2023 and held it in 8 quarters.
  • Caitlin John's Quest Diagnostics position peaked at $984 in Q4 2023.
  • 1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Caitlin John's 13F filing for Q2 2026, filed 17 Aug 2026.